Exploring the Antimicrobial Efficacy of Mesenchymal Stem Cell Secretome Against Klebsiella pneumoniae in Urinary Tract Infections.
Ali L., Sokhn ES., Khalil C., Saleh FA.
Laboratory Study, published in Clin Transl Sci (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Clin Transl Sci (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42273778
- DOI
- 10.1111/cts.70630
Abstract (original English)
Antimicrobial resistance (AMR) has become a global health crisis, with Klebsiella pneumoniae (K. pneumoniae) emerging as a major driver of AMR and a leading cause of urinary tract infections (UTIs). Mesenchymal stem cell (MSC)-derived secretomes have gained attention for their antimicrobial properties. This study aimed to investigate the antibacterial activity of MSC-derived secretomes against urinary K. pneumoniae isolates. The secretomes derived from adipose tissue (AD-MSCs), bone marrow (BM-MSCs), and umbilical cord (UC-MSCs) were tested against 50 K. pneumoniae clinical strains isolated from urine, including extended-spectrum β-lactamase (ESBL)-, AmpC-, and carbapenem-resistant (CRE) strains. This secretome inhibited 68% of isolates overall, including 81.5% of K. pneumoniae (non-ESBL, non-AmpC, non-CRE), 46.7% of ESBL-, and 100% of AmpC-producing isolates, but showed no effect on CRE isolates. Genotypic analysis revealed that all ESBL-producing isolates (100%) harbored the blaSHV gene and expressed the fimH, wabG, uge, ureA, and entB virulence factors. These findings demonstrate, for the first time, the antibacterial potential of three distinct MSC secretome sources against K. pneumoniae, highlighting their promise as a novel adjunctive therapy for drug-resistant UTIs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.